A case reveals prompt systemic therapy improved outcomes in HER2-positive gastric cancer.
We present a case of human epidermal growth factor receptor 2 (HER2)-overexpressing, alpha-fetoprotein (AFP)-producing metastatic gastric adenocarcinoma diagnosed in the USA. Both HER2 overexpression and AFP production are independently associated with poor prognosis in gastric cancer, and their co-expression is rare. This gastric cancer subtype has been reported mainly in Asian populations, with fewer cases in Western countries. Due to its rarity, optimal treatment strategies are not well-established, and clinicians typically treat with standard cytotoxic chemotherapy regimens. Our patient presented with a visceral crisis denoted by impending liver failure, prompting the urgent initiation of first-line systemic therapy with fluorouracil, leucovorin, oxaliplatin and trastuzumab. This resulted in rapid clinical improvement, normalisation of liver function tests and tumour markers, and radiographic response with approximately 50% reduction in hepatic metastatic disease burden. This case underscores the aggressive behaviour and rarity of HER2-positive, AFP-producing gastric cancer, highlighting the critical need for prompt diagnosis and initiation of systemic therapy.
No takes yet. Share an insight, caveat, or question.
Poles et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: